{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:04:30Z","timestamp":1785557070446,"version":"3.56.0"},"reference-count":22,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["YAKUGAKU ZASSHI"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.1248\/yakushi.26-00014","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:15:42Z","timestamp":1785536142000},"page":"709-721","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on the Future of Antibody Therapeutic Use for the Prevention and Treatment of Infectious Diseases","\u611f\u67d3\u75c7\u306e\u4e88\u9632\u30fb\u6cbb\u7642\u306b\u7528\u3044\u3089\u308c\u308b\u6297\u4f53\u533b\u85ac\u54c1\u306b\u95a2\u3059\u308b\u4eca\u5f8c\u306e\u5c55\u671b\uff5eCOVID-19\u30d1\u30f3\u30c7\u30df\u30c3\u30af\u304b\u3089\u306e\u6559\u8a13\uff5e"],"prefix":"10.1248","volume":"146","author":[{"given":"Minoru","family":"Tada","sequence":"first","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) World Health Organization. \u201cStatement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV).\u201d: \u3008https:\/\/www.who.int\/news\/item\/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)\u3009, cited 26 January, 2026."},{"key":"2","unstructured":"2) World Health Organization. \u201cStatement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic.\u201d: \u3008https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic\u3009, cited 26 January, 2026."},{"key":"3","unstructured":"3) Ministry of Health, Labour and Welfare. \u201cResponse to COVID 19 (Novel Coronavirus) after the classification change.\u201d: \u3008https:\/\/www.mhlw.go.jp\/stf\/covid-19\/kenkou-iryousoudan_00006.html\u3009, cited 26 January, 2026."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Khare S., Gurry C., Freitas L., Schultz M. B., Bach G., Diallo A., Akite N., Ho J., Lee R. T., Yeo W., GISAID Core Curation Team, Maurer-Stroh S., <i>China CDC Wkly.<\/i>, <b>3<\/b>, 1049\u20131051 (2021).","DOI":"10.46234\/ccdcw2021.255"},{"key":"5","unstructured":"5) World Health Organization. \u201cGuidelines on the nonclinical and clinical evaluation of monoclonal antibodies and related products intended for the prevention or treatment of infectious diseases.\u201d: \u3008https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-the-nonclinical-and-clinical-evaluation-of-monoclonal-antibodies-and-related-products-intended-for-the-prevention-or-treatment-of-infectious-diseases\u3009, cited 26 January, 2026."},{"key":"6","unstructured":"6) World Health Organization. \u201cGuidelines on clinical evaluation of vaccines: Regulatory expectations. Replacement of Annex 1 of WHO Technical Report Series, No. 924. In: WHO Expert Committee on Biological Standardization: Sixty-seventh report.\u201d: \u3008https:\/\/www.who.int\/publications\/m\/item\/WHO-TRS-1004-web-annex-9\u3009, cited 26 January, 2026."},{"key":"7","unstructured":"7) World Health Organization. \u201cHuman challenge trials for vaccine development: Regulatory considerations, Annex 10, TRS No 1004.\u201d: \u3008https:\/\/www.who.int\/publications\/m\/item\/human-challenge-trials-for-vaccine-a10-trs-no-1004\u3009, cited 26 January, 2026."},{"key":"8","unstructured":"8) World Health Organization. \u201cNonclinical and clinical evaluation of monoclonal antibodies and related products intended for the prevention or treatment of COVID-19.\u201d: \u3008https:\/\/www.who.int\/publications\/m\/item\/nonclinical-and-clinical-evaluation-of-monoclonal-antibodies-and-related-products-intended-for-the-prevention-or-treatment-of-covid-19\u3009, cited 26 January, 2026."},{"key":"9","unstructured":"9) World Health Organization. \u201cNonclinical and clinical evaluation of monoclonal antibodies and related products intended for the prevention of respiratory syncytial virus disease.\u201d: \u3008https:\/\/www.who.int\/publications\/m\/item\/nonclinical-and-clinical-evaluation-of-monoclonal-antibodies-and-related-products-intended-for-the-prevention-of-respiratory-syncytial-virus-disease\u3009, cited 26 January, 2026."},{"key":"10","unstructured":"10) U.S. Food and Drug Administration. \u201cCOVID-19: Developing Drugs and Biological Products for Treatment or Prevention.\u201d: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/covid-19-developing-drugs-and-biological-products-treatment-or-prevention\u3009, cited 26 January, 2026."},{"key":"11","unstructured":"11) U.S. Food and Drug Administration. \u201cDevelopment of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization.\u201d: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-monoclonal-antibody-products-targeting-sars-cov-2-emergency-use-authorization\u3009, cited 26 January, 2026."},{"key":"12","unstructured":"12) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). \u201cPreclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6\uff08R1).\u201d: \u3008https:\/\/www.pmda.go.jp\/int-activities\/int-harmony\/ich\/0058.html\u3009, cited 26 January, 2026."},{"key":"13","unstructured":"13) U.S. Food and Drug Administration. \u201cPotency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens.\u201d: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/potency-assay-considerations-monoclonal-antibodies-and-other-therapeutic-proteins-targeting-viral\u3009, cited 26 January, 2026."},{"key":"14","unstructured":"14) European Medical Agency. \u201cNon-clinical and clinical evaluation of antiviral medicinal products and monoclonal antibodies for the prevention and treatment of COVID-19 - Scientific guideline.\u201d: \u3008https:\/\/www.ema.europa.eu\/en\/non-clinical-clinical-evaluation-antiviral-medicinal-products-monoclonal-antibodies-prevention-treatment-covid-19-scientific-guideline\u3009, cited 26 January, 2026."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tada M., Aoyama M., Ishii-Watabe A., <i>MAbs<\/i>, <b>15<\/b>, 2222874 (2023).","DOI":"10.1080\/19420862.2023.2222874"},{"key":"16","unstructured":"16) Bianchini F., Crivelli V., Abernathy M. E., <i>et al.<\/i>, <i>Sci. Immunol.<\/i>, <b>8<\/b>, eade0958 (2023)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Guenthoer J., Lilly M., Starr T. N., Dadonaite B., Lovendahl K. N., Croft J. T., Stoddard C. I., Chohan V., Ding S., Ruiz F., Kopp M. S., Finzi A., Bloom J. D., Chu H. Y., Lee K. K., Overbaugh J., <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>120<\/b>, e2220948120 (2023).","DOI":"10.1073\/pnas.2220948120"},{"key":"18","unstructured":"18) Dacon C., Peng L., Lin T. H., <i>et al.<\/i>, <i>Cell Host Microbe<\/i>, <b>31<\/b>, 97\u2013111.e112 (2023)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Liu Y., Soh W. T., Kishikawa J. I., <i>et al.<\/i>, <i>Cell<\/i>, <b>184<\/b>, 3452\u20133466.e18 (2021).","DOI":"10.1016\/j.cell.2021.05.032"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kibria M. G., Lavine C. L., Tang W., Wang S., Gao H., Shi W., Zhu H., Voyer J., Rits-Volloch S., Keerti, Bi C., Peng H., Wesemann D. R., Lu J., Xie H., Seaman M. S., Chen B., <i>EMBO Rep.<\/i>, <b>24<\/b>, e57724 (2023).","DOI":"10.15252\/embr.202357724"},{"key":"21","unstructured":"21) U.S. Food and Drug Administration. \u201cFDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs.\u201d: \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs\u3009, cited 26 January, 2026."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Keam S. J., <i>Drugs<\/i>, <b>83<\/b>, 181\u2013187 (2023).","DOI":"10.1007\/s40265-022-01829-6"}],"container-title":["YAKUGAKU ZASSHI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/146\/8\/146_26-00014\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:26:17Z","timestamp":1785554777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/146\/8\/146_26-00014\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/yakushi.26-00014","relation":{},"ISSN":["0031-6903","1347-5231"],"issn-type":[{"value":"0031-6903","type":"print"},{"value":"1347-5231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"26-00014"}}